Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib

被引：0
|
作者：
Zwierenga, F. [1 ]
Muntinghe-Wagenaar, B. [1 ]
Rozendal, P. [1 ]
van der Leest, P. [1 ]
Schuuring, E. [1 ]
van der Wekken, A. J. [1 ]
机构：
[1] Univ Med Ctr Groningen, Groningen, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
ctDNA; EGFR exon 20; resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.06D.02
引用
收藏
页码：S502 / S502
页数：1
相关论文
共 50 条
  • [31] Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
    van Veggel, B.
    Santos, J. F. Vilacha Madeira R.
    Hashemi, S. M. S.
    Paats, M. S.
    Monkhorst, K.
    Heideman, D. A. M.
    Groves, M.
    Radonic, T.
    Smit, E. F.
    Schuuring, E.
    van der Wekken, A. J.
    de Langen, A. J.
    LUNG CANCER, 2020, 141 : 9 - 13
  • [32] Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer
    van Veggel, B.
    van der Wekken, A.
    Hashemi, S.
    Cornelissen, R.
    Monkhorst, K.
    Heideman, D.
    Radonic, T.
    Smit, E. F.
    Schuuring, E.
    De Langen, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)
    Neal, Joel W.
    Li, Ying
    Yu, Ziji
    Fram, Robert J.
    Danes, Christopher
    Vincent, Sylvie
    Piotrowska, Zofia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] CEREBROSPINAL FLUID-DERIVED CIRCULATING TUMOR DNA IS SUPERIOR TO PLASMA IN NSCLC PATIENTS WITH CNS PROGRESSION
    Yang, Hainan
    Wen, Lei
    Zhou, Caicun
    NEURO-ONCOLOGY, 2022, 24 : 22 - 22
  • [35] Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
    Bazhenova, Lyudmila
    Minchom, Anna
    Viteri, Santiago
    Bauml, Joshua M.
    Ou, Sai-Hong Ignatius
    Gadgeel, Shirish M.
    Manuel Trigo, Jose
    Backenroth, Daniel
    Li, Tracy
    Londhe, Anil
    Mahadevia, Parthiv
    Girard, Nicolas
    LUNG CANCER, 2021, 162 : 154 - 161
  • [36] Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study
    Shi, Meiqi
    Chen, Ping
    Cui, Bin
    Yao, Yuanhu
    Wang, Juanyi
    Zhou, Tong
    Wang, Li
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [37] Molecular characteristics of EGFR exon 20 uncommon R776H mutation and response to osimertinib in NSCLC patients.
    An, Gaili
    He, Li
    Wang, Xifang
    Lei, Yu
    Gu, Dejian
    Chen, Rongrong
    Xia, Xuefeng
    Bai, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Osimertinib, an irreversible mutant selective EGFR tyrosine kinase inhibitor, exerts anti tumor activity in NSCLC harbouring exon 20 insertion mutant-EGFR
    Floc'h, Nicolas
    Ashton, Susan
    Bianco, Ambra
    Colclough, Nicola
    Cross, Darren A. E.
    Cuomo, Maria Emanuela
    Finlay, M. Raymond V.
    Martin, Matthew J.
    Menard, Ludovic
    McKerrecher, Darren
    O'Neill, Daniel J.
    Orme, Jonathan P.
    Staniszewska, Anna D.
    Ward, Richard A.
    Yates, James W. T.
    CANCER RESEARCH, 2017, 77
  • [39] Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study
    Karayama, Masato
    Suda, Takafumi
    Yoh, Kiyotaka
    Usui, Kazuhiro
    Hosomi, Yukio
    Kishi, Kazuma
    Naka, Go
    Watanabe, Kageaki
    Tamano, Shu
    Uemura, Kohei
    Kunitoh, Hideo
    LUNG CANCER, 2024, 198
  • [40] Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M-Positive NSCLC
    Liao, Bin-Chi
    Hsu, Wei-Hsun
    Lee, Jih-Hsiang
    Yang, Ching-Yao
    Tsai, Tzu-Hsiu
    Liao, Wei-Yu
    Ho, Chao-Chi
    Lin, Chia-Chi
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Soo, Ross A.
    Yang, James Chih-Hsin
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (01):
12345